Important note
This AI stock analysis for ADMA Biologics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
ADMA Biologics - AI Stock Analysis
Analysis generated July 22, 2024
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics. The company's primary focus is on the treatment of immune deficiencies and infectious diseases, particularly through its plasma-derived products. As a player in a niche but crucial segment of the pharmaceutical industry, ADMA Biologics aims to cater to unmet medical needs while maintaining a robust pipeline for future products.
Fundamental Analysis
Revenue Growth: For the last quarter, ADMA Biologics reported revenues of $82M. This figure represents a 10.79% increase from the previous quarter and a substantial 43.86% rise compared to the same quarter last year. Both of these growth metrics are very positive signs of the company's ability to expand its market reach and increase sales, a crucial indicator of growth for a biotech firm.
Net Income: The net income for the last quarter was $18M. This is a remarkable improvement of 200.92% compared to the previous quarter and an astonishing 362.28% increase year-over-year. This indicates not only operational efficiency but also enhanced profitability, which can drive the stock's upward movement.
EBITDA: The EBITDA for the last quarter was $24M, marking a 48.60% increase compared to the prior quarter and a staggering 1,891.07% rise from the same quarter last year. This enormous year-over-year boost highlights exceptional performance and profitability growth, indicating significant improvements in the company's financial health.
Technical Analysis
The current stock price of ADMA Biologics is $13.75. This price has increased by 25.00% compared to a month ago and an incredible 259.95% compared to a year ago, thus reflecting a strong bullish trend in the stock's performance.
The Simple Moving Average over 10 days (SMA10) is 13.29, which is higher than the previous SMA10 of 13.19. This indicates ongoing upward momentum in the stock's price movement.
Moreover, the Relative Strength Index (RSI) stands at 63.9, indicating a neutral condition that is closer to the overbought territory. A neutral RSI suggests that the stock is neither overbought nor oversold, providing investors a balanced perspective.
Alternative Data Analysis
Job Postings and Employee Sentiment: ADMA Biologics currently has 95 open positions, down by 6% in the last couple of months. This decline might indicate attempts to improve margins or manage costs, possibly reflecting a conservatism in operational expansion.
Employee sentiment is reported as neutral, neither overwhelmingly positive nor negative, suggesting a stable internal environment.
Customer Acquisition and Engagement: ADMA Biologics has an estimated 13,000 visitors to their webpage monthly, with no significant fluctuations in recent times. Their Twitter engagement also remains stagnant, with 460 followers, reflecting stability in customer engagement metrics.
According to AltIndex's AI score, ADMA Biologics holds a score of 53, which corresponds to a 'hold' signal. This score balances various factors, including fundamental, technical, and alternative data points.
Conclusion and Recommendation
Based on the comprehensive analysis provided, ADMA Biologics demonstrates robust financial performance characterized by significant year-over-year growth in revenue, net income, and EBITDA. The technical indicators affirm the stock's bullish trend, while the SMA and RSI suggest potential for continued, albeit cautious, upward movement.
However, the slight decline in job postings and neutral employee sentiment paired with stable but unimpressive customer engagement metrics warrant cautious optimism. Given the balanced AI score and considering all the other aspects, the recommendation would be to hold the stock. Investors might want to monitor further developments in financial performance and operational metrics for any potential upside.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
